Abstract
NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Current Pharmaceutical Design
Title: NGAL is a Precocious Marker of Therapeutic Response
Volume: 17 Issue: 8
Author(s): Valeria Cernaro, Davide Bolignano, Valentina Donato, Antonio Lacquaniti, Antoine Buemi, Eleonora Crascì, Silvia Lucisano and Michele Buemi
Affiliation:
Keywords: NGAL, acute renal failure, chronic kidney disease, clinical nephrology, clinical pharmacology, glomerulonephritis, vasculitis, antimicrobial, gentamicin, microalbuminuria, Crohn's disease, flogistic, Infliximab, idiopathic, streptozotocin, angiotensin, sepsis, inefficacy, etiologic, immunosuppressors
Abstract: NGAL (Neutrophil Gelatinase-Associated Lipocalin) is a small 25-kD peptide belonging to the lipocalin superfamily. Several studies highlight its role as an organ injury and disease activity biomarker. In the present review, instead, we wanted to study NGAL as a precocious marker of therapeutic response in renal and non-renal diseases (glomerulonephritis, vasculitis, LES, Crohns disease and other chronic inflammatory pathologies). The obtained outcomes support the hypothesis that NGAL could be employed as a biomarker of response to different therapeutic schemes, because its levels sensibly and precociously change compared to other haematologic and biochemical parameters.
Export Options
About this article
Cite this article as:
Cernaro Valeria, Bolignano Davide, Donato Valentina, Lacquaniti Antonio, Buemi Antoine, Crascì Eleonora, Lucisano Silvia and Buemi Michele, NGAL is a Precocious Marker of Therapeutic Response, Current Pharmaceutical Design 2011; 17 (8) . https://dx.doi.org/10.2174/138161211795428939
DOI https://dx.doi.org/10.2174/138161211795428939 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of B Cells in Multiple Sclerosis: Implications for B-Cell-Targeted Therapy
Current Medicinal Chemistry Cefpodoxime Proxetil-Related Hemolysis and Acute Interstitial Nephritis
Current Drug Safety TRP Channels: Emerging Links Between Ca2+, Kidney and Hypertension
Current Hypertension Reviews A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Current Research on Opioid Receptor Function
Current Drug Targets Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Therapeutic AIDS Vaccines
Current Pharmaceutical Design Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Vascular Inflammation During Human Rickettsioses: An Essential Host Response and a Potential Target for Supplemental Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Potential Application of Non-flavonoid Phenolics in Diabetes: Antiinflammatory Effects
Current Medicinal Chemistry Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Haemostatic Activation in HIV Infected Patients Treated with Different Antiretroviral Regimens
Current HIV Research Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology Cyclophosphamide: Time to Say Goodnight and Goodbye?
Current Rheumatology Reviews Reactive Oxygen Species: Physiological Roles in the Regulation of Vascular Cells
Current Molecular Medicine